Physician profile
Stephen M Schinker
NPI 1134304173
$3,617.37
in general payments reported to CMS, 2019-2025
30 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $184 · 2021: $343 · 2022: $616 · 2023: $687 · 2024: $660 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045 · Education: $59.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.45 |
| Education | $59.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $527.11 | 2019-2025 | Farxiga, Lokelma |
| Alexion Pharmaceuticals, INC. | $234.59 | 2022-2024 | Ultomiris |
| Opko Pharmaceuticals, LLC | $221.62 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $217.26 | 2022-2025 | |
| Amgen INC. | $210.07 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Mallinckrodt Hospital Products INC. | $196.87 | 2020-2024 | Acthar |
| Travere Therapeutics, INC. | $195.16 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $185.58 | 2019-2023 | Veltassa, Korsuva |
| Takeda Pharmaceuticals U.S.A., INC. | $173.46 | 2019-2024 | Livtencity |
| Glaxosmithkline, LLC. | $169.12 | 2020-2025 | Benlysta, Arexvy, Shingrix |
| Ardelyx, INC. | $161.52 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $139.69 | 2020-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $120.03 | 2019-2025 | Jynarque |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Ani Pharmaceuticals, INC. | $95.89 | 2022-2023 | Purified Cortrophin Gel |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $95.18 | 2024-2025 | |
| Veloxis Pharmaceuticals, INC. | $85.07 | 2022-2025 | Envarsus |
| Aurinia Pharma U.S., INC. | $73.66 | 2021-2024 | Lupkynis |
| Lilly USA, LLC | $57.36 | 2023-2025 | Jardiance |
| Daiichi Sankyo INC. | $56.99 | 2019-2020 | |
| Horizon Therapeutics Plc | $44.50 | 2022-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.32 | 2023-2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.79 | 2021-2023 | Jardiance |
| Genzyme Corporation | $37.89 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $29.45 | 2022 | |
| Renalytix Ai, INC. | $23.96 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $22.50 | 2025 | Ozempic |
| Genentech USA, INC. | $20.82 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.15 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Schinker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.